Bifogade filer
20240109_PM_Isofol_New CEO_final
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The information in the press release is intended for investors.
Petter Segelman Lindqvist has a MSc in Business and Economics from the Stockholm School of Economics, Sweden, and EM Lyon, France. He has experiences from leading positions in the pharmaceutical industry, including within GlaxoSmithKline, AbbVie and Sobi (Swedish Orphan Biovitrum), as well as from board work in smaller biotech companies. He contributes with knowledge of strategic business development and partnerships, global commercialization, and product development. He has led several product launches and has taken drug candidates through clinical development and regulatory processes to market introduction.
Petter Segelman Lindqvist succeeds Roger Tell who has been acting CEO since June 2023.
"The Board of Directors welcomes Petter Segelman Lindqvist as the new CEO of Isofol. His long experience in business development and negotiations within the pharmaceutical industry will strengthen the company on its way forward. We would also like to take the opportunity to thank Roger Tell for assuming the role as acting CEO since last summer," says Jan-Eric Österlund, Chairman of the Board of Isofol.
"I am looking forward to taking on the CEO role at Isofol. Together with my new colleagues, I will do my utmost to realize the full potential of arfolitixorin, a drug candidate that has distinct potential benefits for a broad group of cancer patients who are still in need of better treatment options," says Isofol´s incoming CEO, Petter Segelman Lindqvist.
For more information, please contact
Isofol Medical AB (publ)
Jan-Eric Österlund, Chairman of the Board
E-mail: jan-eric@osterlund.co.uk
Phone: +44 7785 368 155
This information is information that Isofol Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:40 CET on January 9, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.